Table 1

Odds ratio (OR) analysis of haemorrhagic transformation in trials of thrombolytic agents in acute ischaemic stroke

TrialAll types of haemorrhagesSymptomatic haemorrhagesFatal haemorrhages
Agent oddsPlacebo oddsOR (agent/placebo)95% CIAgent oddsPlacebo oddsOR (agent/placebo)95% CIAgent oddsPlacebo oddsOR (agent/placebo)95% CI
ECASS134/179113/1941.30.93–1.7735/2789/2984.21.97–8.8319/2947/3002.81.15–6.69
NINDS I+II34/27811/3013.31.66–6.7320/2922/31010.62.46–45.829/3031/3119.21.16–73.36
MAST-E49/8817/1163.82.04–7.0424/1134/1296.82.31–20.34
MAST-I39/11816/1402.91.54–5.4410/1471/15510.51.33–83.40
ASK56/11828/1382.31.40–3.9223/1515/1614.91.82–13.2317/1573/1635.91.69–20.47
  • The response to rt-PA or streptokinase treatment is shown by the OR for different trials. The OR is measured by dividing the odds for a certain outcome event of the rt-PA group (numerator) by the odds for this event of the placebo group (denominator). An OR of 1 means that the thrombolytic agent did not affect the incidence of haemorrhages. If the 95% CI does not cover unity, the incidence of haemorrhages is significantly enhanced or diminished by the treatment. — = not available. In all trials a significant increase in all types of haemorrhages, of symptomatic haemorrhages, and of fatal haemorrhages was found. The NINDS trial showed the highest relative risk for fatal haemorrhages.